ClinicalTrials.gg
RecruitingNCT07861971rebond-jasUpdated Oct 6, 2026

Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission

An observational study in Solid and Hematologic Cancer, sponsored by Institut Paoli-Calmettes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Institut Paoli-Calmettes · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
19
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes — 4 open to participants now, 4 under way, none of them phase 3. Hematologic Neoplasms · Institut Paoli-Calmettes.

Started
2026
the only one that year
Observational
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes, this one is the only one that started in 2026, is one of 2 observational ones, and was the 10th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

4 of the 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes, or all of them as a file.
02

Study summary

This is a single-center, non-randomized feasibility study. For this study, 19 young adults treated for cancer at the Paoli-Calmettes Institute will be included.This study includes interviews and questionnaires to assess the adherence rate. It will be measured by the percentage of patients who attend the first two coaching sessions (either in person or via videoconference) relative to the total number of patients included in the study.

The invitation to participate in this program will be made by the surgeon, hematologist, oncologist, or radiation therapist.

Read the detailed description

The first coaching session must take place within one month following inclusion. Coaching sessions will involve all patients enrolled in the study.

Coaching sessions with the coach will be offered as monthly individual interviews over a period ranging from 2 to 6 months. The frequency of sessions will be co-determined by the coach and the participant, depending on the participant's needs. The coach will aim to schedule sessions with at least one month between them. Therefore, patients will have a minimum of 2 and a maximum of 6 onco-coaching sessions.

Sessions will be held at the Faculty of Sports Sciences, in a dedicated office. The first session must be conducted in person. Subsequent sessions may be conducted remotely (by phone or videoconference), depending on patient preferences. This option is supported by findings from recent studies (McCann et al., 2019; Mostafa et al., 2025; Zhong et al., 2025).

During sessions, the coach uses standard motivational interviewing techniques (Miller, 1983). Through the use of open-ended questions, active and reflective listening, positive reinforcement and validation techniques, as well as regular reformulation of what is expressed, the coach reveals contradictions and ambivalence, defuses resistance, and promotes self-determined strategies for change (Miller and Rollnick, 2002).

From the first session, the coach works with each participant to define personalized goals and a strategy to achieve them, including identifying available resources. Each session should last between 45 minutes and 1 hour.Questionnaires:

QEEC-AYAs: A tool designed to measure the psychosocial needs of adolescents and young adults during and after treatment. Developed by Justafré et al. (2023), it includes 48 items divided into 7 dimensions: information (8 items), care team (6 items), physical health (4 items), emotional health (14 items), sexual and reproductive health (6 items), health behaviors and well-being (4 items), and daily life (6 items). The questionnaire demonstrates strong psychometric properties, with Cronbach's alpha values above 0.80.

Interviews:

These semi-structured interviews will be conducted to analyze the impact of the intervention on patients and to better understand the underlying processes. They will be carried out by researchers specialized in social psychology and quantitative data analysis, using a semi-structured adaptive interview guide. Each interview will last between 30 minutes and 1 hour.

The first semi-structured interview will be conducted in a room at the Faculty of Sports Sciences by at least two researchers. The second interview may be conducted either remotely or in person at the Faculty of Sports Sciences.

All interviews must be recorded using a voice recorder, then pseudonymized (only the study ID number) and transferred to the secure server of the Management Sport Cancer laboratory. The recordings must then be deleted from the voice recorder.

03

Conditions studied

  • Solid and Hematologic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male or female aged 18 to 25 at the time of cancer diagnosis and/or at the time of inclusion.In complete remission, within one year following the end of treatment and at the time of inclusion

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 25 at the time of cancer diagnosis and/or at the time of inclusion.
  • In complete remission, within one year following the end of treatment and at the time of inclusion.
  • Treated at the Comprehensive Cancer Center Institut Paoli-Calmettes.
  • Able to speak and write in French.
  • Has not objected to participation in the study.
  • Affiliated with a social security scheme or beneficiary of such a scheme.

Non -Inclusion Criteria:

  • Patient undergoing treatment, except for maintenance therapy.
  • Patient experiencing a relapse.
  • Person in an emergency situation, legally protected adult (under guardianship, curatorship, or judicial protection), or unable to express non-opposition.
  • Patient with clinically confirmed psychological symptoms (e.g., receiving antidepressants, mood stabilizers, anxiolytics, etc.).
  • Inability to comply with study follow-up due to geographic, social, or psychological reasons.

Exclusion criteria

Exclusion Criteria:

Relapse occurring between inclusion and the second onco-coaching session.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
19 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The primary objective of the study is to assess the feasibility of a sport-inspired onco-coaching program by evaluating the participation rate of young adults in the first two coaching sessions.

    The primary evaluation criterion of the study will be the adherence rate to the onco-coaching program. It will be measured by the percentage of patients who attend the first two coaching sessions (either in person or via videoconference) relative to the total number of patients enrolled in the study. The invitation to participate in the program will be made by the surgeon, hematologist, oncologist, or radiation therapist.

    Time frame: 2 years

Secondary outcomes

  1. To identify the success and failure factors of the extrahospital support program through qualitative interviews.

    Assessment of participants' satisfaction with the program through semi-structured interviews

    Time frame: 2 years

  2. To evaluate overall adherence to the onco-coaching program

    Compliance with the onco-coaching program, measured empirically across all scheduled visits by assigning equal weight to all participants, regardless of the number of visits planned.

    Time frame: 2 years

  3. To collect and characterize the reasons why patients decline to participate in the study

    Number of refusals to sign the informed consent form.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 24 months after the start.

Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 24 months is below that.

Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 6, 2026
StartActual
Aug 3, 2026
Primary completionEst.
Aug 3, 2028
CompletionEst.
Aug 3, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861971
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Aug 3, 2026
Primary completion
Aug 3, 2028 (estimated)
Completion
Aug 3, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

jihane pakradouni, PhD
Contact
DRCI.UP@ipc.unicancer.fr
+33491223778

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion